Workflow
ARS Pharmaceuticals(SPRY)
icon
Search documents
ARS Pharmaceuticals(SPRY) - 2021 Q3 - Quarterly Report
2021-11-10 21:23
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 Silverback Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-1489190 (State or oth ...
Silverback Therapeutics (SBTX) presents at ESMO Congress 2021
2021-09-27 20:59
SBT6050-101: Phase 1/1B Interim Clinical Study Update Investor Presentation at the European Society of Medical Oncology 2021 September 16, 2021 Forward-looking statements and disclaimers Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of any of its contents is prohibited. This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any ...
ARS Pharmaceuticals(SPRY) - 2021 Q2 - Quarterly Report
2021-08-12 20:37
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 Silverback Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 81-1489190 | | --- | --- ...
Silverback Therapeutics (SBTX) Investor Presentation - Slideshow
2021-07-16 20:46
| --- | --- | --- | |----------|-------|-------| | | | | | SILVERB/ | | | Forward-looking statements and disclaimers Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of any of its contents is prohibited. This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statement ...
ARS Pharmaceuticals(SPRY) - 2021 Q1 - Quarterly Report
2021-05-13 20:21
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39756 Silverback Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-1489190 ...
Silverback Therapeutics (SBTX) Investor Presentation - Slideshow
2021-04-12 20:48
| --- | --- | --- | |---------|-------|-------| | | | | | SILVERI | | | Forward-looking statements and disclaimers Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of any of its contents is prohibited. This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements ...
ARS Pharmaceuticals(SPRY) - 2020 Q4 - Annual Report
2021-03-29 20:13
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39756 Silverback Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-1489190 (Sta ...
Silverback Therapeutics (SBTX) Investor Presentation - Slideshow
2021-03-08 12:23
| --- | --- | --- | |---------|-------|-------| | | | | | SILVERI | | | Forward-looking statements and disclaimers Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of any of its contents is prohibited. This presentation includes certain projections and forward-looking statements as of the date of this presentation provided by Silverback Therapeutics, Inc. (the "Company"). The information in this presentation is current only as of its date and may have changed sin ...